U.S. researchers have found that a supplemental protein may help restore impaired mobility of people who suffer from a stroke.
Naturally occurring in humans, the protein has proved to work well in restoring motor function in rats after a stroke, according to two new studies by researchers at the University of California, Irvine (UCI).
The researchers hope that the protein will also help humans.
Administered directly to the brain, the protein restores 99 percent of lost movement; if it’s given through the nose, 70 percent of lost movement is regained. Untreated rats improve by only 30 percent.
Report of the Brain Tumor Progress
Roland "Bud" Henrich, 61, was the first stroke patient to be enrolled in a Phase I trial using his own stem cells.
For the first time in the United States, a stroke patient has been intravenously injected with his own bone marrow stem cells as part of a research trial at The University of Texas Medical School at Houston.
Sean Savitz, M.D., assistant professor of neurology at The University of Texas Medical School at Houston, leads a first-of-its-kind bone marrow stem cell therapy study for stroke patients.
Roland “Bud” Henrich, 61, was transferred to Memorial Hermann – Texas Medical Center
Apparently it looks like a simple tea bag but in reality it’s a genetically engineered concentrate able to completely revolutionize treatments for stroke patients. A special little bag called ‘CellBeads’ contains tiny capsules, each containing about 1 million stem cells. Thanks to genetic engineering techniques, stem cells taken from the bone marrow are transformed into a drug that protects brain cells from dying. This allows the cells to be rejuvenated and repair damage caused by the stroke. The stem cells are encapsulated to ‘fool’ the immune system, avoiding a rejection by the body. ‘CellBeads’ were developed by
Image via Wikipedia
The first patient in the landmark Pilot Investigation of Stem Cells in Stroke (PISCES) trial has been treated with neural stem cells. The study is the first fully regulated clinical trial of neural stem cell therapy for stroke. Investigators will evaluate the safety of ReNeuron cells in disabled ischemic stroke patients.
“This is a first in man safety study,” lead investigator Keith Muir, MD, from the University of Glasgow‘s Institute of Neuroscience and Psychology in Scotland, explained to Medscape Medical News. “We are looking at neurological effects — clinical and imaging — only as secondary goals.”
The stem cells
Stem Cell Therapeutics Corp. or the wishes to announce the acceptance and publication of the paper entitled “The Beta-hCG + Erythropoietin in Acute Stroke (BETAS) Study” by the journal “Stroke”, on March 8, 2010.
This paper was authored by Dr. Steven C. Cramer, from the University of California, Irvine, Dr. David Brown at Hoag Memorial Hospital Presbyterian, New Port Beach, Dr. Michael D. Hill of Foothills Hospital at the University of Calgary, and colleagues.
Dr. Allen Davidoff, VP of Product Development, commented as follows:
“The Stroke journal, published by the American Heart Association, is the top journal in the field of stroke